Education
About Us
Working with TipRanks
Follow Us
Telix Pharmaceuticals Ltd. (TLPPF)
OTHER OTC:TLPPF
RESEARCH TOOLSreports
TLPPF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.35 - $24.85
Previous CloseN/A
Volume500.00
Average Volume (3M)4.90K
Market Cap
$6.35B
Enterprise Value$6.22B
Total Cash (Recent Filing)AU$25.77M
Total Debt (Recent Filing)AU$1.73M
Price to Earnings (P/E)181.3
Beta1.35
Next Earnings
Aug 21, 2025EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding336,872,300
10 Day Avg. Volume5,218
30 Day Avg. Volume4,904
Standard Deviation0.20
R-Squared0.37
Alpha0.04
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)N/A
Price to Sales (P/S)20.69
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$21.19Price Target Upside17.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Telix Pharmaceuticals Ltd. News
PremiumCompany Announcements
Telix Pharmaceuticals Director Alters Shareholding
PremiumCompany Announcements
Telix Pharmaceuticals Executives Complete Major Share Sale
PremiumCompany Announcements
Telix CEO to Sell Shares for Personal Reasons
PremiumCompany Announcements
FDA Accepts Telix’s Kidney Cancer Imaging Agent for Priority ReviewPremiumCompany Announcements
Telix Pharmaceuticals Announces Board Renewal and Leadership Changes
PremiumCompany Announcements
Telix Pharmaceuticals Shifts Reporting Currency to USD
PremiumCompany Announcements
Telix Pharmaceuticals Reports Strong 2024 Growth and Expansion Plans
---
Bulls Say, Bears Say
Bulls Say
Product ApprovalsNew product approvals such as Zircaix and Pixclara could significantly contribute to the company's revenue.
Revenue GuidanceThe 2025 revenue guidance is 17% above consensus, which indicates strong expected growth for the company.
Bears Say
Product DelayZircaix revenue is delayed to the second half of 2025 due to the NDA resubmission requirement.
---
Options Prices
Currently, No data available
---
Ownership Overview
6.94% Insiders
2.99% Mutual Funds
― Other Institutional Investors
93.08% Public Companies and Individual Investors
TLPPF FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest stock price was $7.35 and its highest was $24.85 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is $6.35B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 21, 2025 which is in 170 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Feb 20, 2025. The company reported $0.087 earnings per share for the quarter, the consensus estimate of $0.087 by $0.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is 0.18.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 336,872,300 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of $0.087 in its last earnings report, expectations of $0.087. Following the earnings report the stock price went up 2%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in TLPPF
---
Telix Pharmaceuticals Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.19 (17.33% Upside)
$21.19 (17.33% Upside)
Blogger Sentiment
Bullish
TLPPF Sentiment 96%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $36.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
129.12%
12-Months-Change
Fundamentals
Return on Equity
14.52%
Trailing 12-Months
Asset Growth
244.30%
Trailing 12-Months
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.
---
TLPPF Company Deck
---
TLPPF Earnings Call
Q4 2025
0:00 / 0:00
---
TLPPF Stock 12 Month Forecast
Average Price Target
$21.19
▲(17.33% Upside)
Technical Analysis
Opthea Limited
―
CSL
―
Mesoblast Limited
―
Race Oncology Ltd.
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―
Best Analysts Covering TLPPF
1 Year
1 Year Success Rate
25/26 ratings generated profit
1 Year Average Return
+75.12%
reiterated a buy rating 11 days ago
Copying Shane Storey's trades and holding each position for 1 Year would result in 96.15% of your transactions generating a profit, with an average return of +75.12% per trade.
---